At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 313 enrolled
Drug / intervention
genakumab +3 moredrug
Likely dose
genakumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety & Efficacy of Genakumab in Patients With Frequent Flares
Changchun GeneScience Pharmaceutical Co., Ltd.·interventional·Posted Aug 9, 2023·Updated Dec 18, 2024
In Brief
A Phase 3 clinical trial evaluating genakumab, placebo for Diprospan, and 2 other interventions for Acute Gout Arthritis. Completed, enrolled 313 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Gout Arthritis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedAug 2023
Primary CompletionApr 2024
TodayJul 2026
First PostedAug 9, 2023
Enrollment StartJan 11, 2023
Primary CompletionApr 3, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.9 years ago
Interventions
genakumabdrug
200mg s.c.
placebo for Diprospandrug
i.m.
placebo for genakumabdrug
s.c.
Diprospandrug
7mg i.m.